Protocol No.: EAY191-N4

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
Principal Investigator
Pfaendler, Krista
Phase
II
Age Group
Adult
Applicable Disease Site
Gynecologic Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Jill Stone, LPN
Research Specialist
Phone: +1 304-634-4417

View on ClinicalTrials.gov